Amgen Stock Forecast for 2022 - 2025 - 2030
Updated on 09/30/2022
Amgen Stock Forecast and Price Target
Amgen's most recent price target of $255.00 for 2022 was provided by thridteen renowned analysts over the past few months, with an average prediction of $255.00. If this prediction is correct, Amgen's stock could rise by 11.64 percent from its current trading price. The potential increase for the stock is $255.00 per share, with a possible range of $182.00 to $295.00. If you are interested in AMGN stock, you should also look at its competitors.
11.64% Upside
Amgen Fair Value Forecast for 2022 - 2025 - 2030
Amgen's Price has increased by 18.75% In the last three years, going from $197.71 to $234.78. In the next year, analysts expect Fair Value to reach $241.92 – an increase of 3.04%. For the next nine years, the forecast is for Fair Value to grow by 41.11%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
12
|
$164.53 | $185.07 | 10.62% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$330.01 | $333.19 | 6.06% |
| ROG Stock Forecast | Roche Holding | Outperform |
18
|
CHF320.25 | CHF384.23 | 17.10% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$142.72 | $164.23 | 9.30% |
| PFE Stock Forecast | Pfizer | Outperform |
3
|
$44.16 | $56.27 | 20.02% |
Amgen Revenue Forecast for 2022 - 2025 - 2030
Amgen's Revenue has increased by 9.40% In the last three years, going from $23.75B to $25.98B. In the next year, analysts expect Revenue to reach $26.12B – an increase of 0.54%. For the next nine years, the forecast is for Revenue to grow by 7.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
18
|
kr764.70 | kr678.96 | 17.37% |
| MRK Stock Forecast | Merck | Outperform |
6
|
$86.64 | $99.57 | 15.42% |
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
18
|
$516.61 | $658.24 | 30.66% |
Amgen Dividend per Share Forecast for 2022 - 2025 - 2030
In the last three years, Amgen's Dividend per Share has grown, increasing from $5.28 to $7.04 – a growth of 33.33%. The next year looks promising for Amgen, with analysts predicting Dividend per Share of $7.61 – an increase of 8.10%. Over the next nine years, experts anticipate that Amgen's Dividend per Share will grow at a rate of 79.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| DHR Stock Forecast | Danaher | Outperform |
16
|
$262.15 | $321.60 | 23.97% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$98.29 | $128.88 | 27.68% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£99.33 | £136.08 | 41.24% |
Amgen Free Cash Flow Forecast for 2022 - 2025 - 2030
In the last three years, Amgen's Free Cash Flow has gone down from $10.56B to $8.38B – a 20.62% drop. Next year, analysts are expecting Free Cash Flow to reach $10.13B – an increase of 20.85%. Over the next nine years, the forecast is for Free Cash Flow to grow by 46.35%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
18
|
CHF74.92 | CHF103.75 | 18.89% |
| BMY Stock Forecast | Bristol-Myers Squibb | Outperform |
2
|
$71.71 | $79.05 | 15.74% |
| MDT Stock Forecast | Medtronic | Outperform |
18
|
$82.27 | $106.84 | 28.84% |
Amgen Net Income Forecast for 2022 - 2025 - 2030
In the last three years, Amgen's Net Income has seen a drop from $8.39B to $5.89B – a 29.80% decrease. For the next year, analysts are expecting Net Income to reach $9.57B – an increase of 62.41%. Over the next nine years, experts predict that Net Income will grow by 67.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| SAN Stock Forecast | Sanofi | Outperform |
18
|
77.84€ | 104.66€ | 41.32% |
| GILD Stock Forecast | Gilead Sciences | Outperform |
11
|
$63.07 | $69.65 | 12.57% |
| VRTX Stock Forecast | Vertex Pharmaceuticals | Outperform |
16
|
$292.80 | $294.18 | 4.85% |
Amgen EBITDA Forecast for 2022 - 2025 - 2030
In the last three years, Amgen's EBITDA has grown by 0.81%, rising from $12.48B to $12.58B. For next year, analysts predict EBITDA of $15.95B, which would mean an increase of 26.77%. Over the next nine years, experts predict that Amgen's EBITDA will grow at a rate of 4.03%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$691.82 | $696.64 | 9.57% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$150.95 | $235.45 | 49.06% |
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
18
|
163.60€ | 147.51€ | 28.36% |
Amgen EBIT Forecast for 2022 - 2025 - 2030
In the last three years, Amgen's EBIT has decreased from $10.55B to $9.34B – a 11.50% drop. For next year, analysts predict EBIT of $12.42B, which would mean an increase of 33.01%. Over the next nine years, experts predict that Amgen's EBIT will grow at a rate of 35.96%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
16
|
$112.30 | $147.79 | 21.99% |
| GSK Stock Forecast | GSK | Outperform |
16
|
£13.16 | £16.08 | 38.30% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.03k | ¥0.00 | 16.63% |
Amgen EPS Price Prediction Forecast for 2022 - 2025 - 2030
Amgen's EPS has increased by 18.75% In the last three years, going from $14.40 to $17.10. In the next year, analysts expect EPS to reach $17.62 – an increase of 3.04%. For the next nine years, the forecast is for EPS to grow by 41.11%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Outperform |
7
|
47.72€ | 67.79€ | 66.60% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.63k | ¥0.00 | 23.97% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
16
|
¥3.78k | ¥0.00 | 16.53% |